IGC Pharma, Inc. (IGC) Revenue History
Annual and quarterly revenue from 2006 to present
IGC Revenue Over Time (2006–2026)
IGC Revenue Growth History
9 of 20 years with positive growth- FY2006 revenue growth
- N/A
- FY2007 revenue growth
- -463.3%
- FY2008 revenue growth
- +386.0%
- FY2009 revenue growth
- +1515.1%
- FY2010 revenue growth
- -49.4%
- FY2011 revenue growth
- -77.2%
- FY2012 revenue growth
- +3.1%
- FY2013 revenue growth
- +91.2%
- FY2014 revenue growth
- -71.7%
- FY2015 revenue growth
- +237.9%
- FY2016 revenue growth
- -17.1%
- FY2017 revenue growth
- -90.9%
- FY2018 revenue growth
- +277.9%
- FY2019 revenue growth
- +133.3%
- FY2020 revenue growth
- -20.4%
- FY2021 revenue growth
- -77.9%
- FY2022 revenue growth
- -55.8%
- FY2023 revenue growth
- +129.5%
- FY2024 revenue growth
- +47.6%
- FY2025 revenue growth
- -5.5%
- FY2026 revenue growth
- -6.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2026 | $317K | -3.9% |
| Q3 2026 | $350K | +36.2% |
| Q2 2026 | $191K | -53.6% |
| Q1 2026 | $328K | +20.6% |
| Q4 2025 | $330K | +11.9% |
| Q3 2025 | $257K | +26.0% |
| Q2 2025 | $412K | +41.6% |
| Q1 2025 | $272K | -51.0% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
IGC's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
IGC Revenue Analysis (2006–2026)
Current Revenue & Growth
As of June 30, 2026, IGC Pharma, Inc. (IGC) generated trailing twelve-month (TTM) revenue of $1.2 million, reflecting slight decline in growth of -3.9% year-over-year. The most recent quarter (Q4 2026) recorded $317,000 in revenue, down 9.4% sequentially.
Historical Growth Trajectory
IGC's 5-year compound annual growth rate (CAGR) stands at +5.7%, indicating steady revenue expansion. The 3-year CAGR of +9.2% exceeds the 5-year average, indicating an acceleration in the most recent period. IGC Pharma, Inc.'s highest annual revenue of $35.3 million was recorded in 2009.
Revenue by Segment
IGC's revenue is primarily driven by Tolling White Labeling Service Member (91%), and WellnessAndLifestyleMember (9%). With over half of revenue concentrated in Tolling White Labeling Service Member, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including TLRY (+3.0% YoY), SNDL (+1.1% YoY), and ATAI (+87.2% YoY) — IGC has underperformed the peer group in revenue growth. Compare IGC vs TLRY →
IGC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IGCCurrent | $1M | -3.9% | +5.7% | -860.3% | |
 TLRY | $1.1B | +3.0% | +22.7% | -277.9% | |
 SNDL | $946M | +1.1% | +73.1% | -0.5% | |
 ATAI | $4M | +87.2% | - | -2439.7% |
IGC Historical Revenue Data (2006–2026)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2026 | $1.2M | -6.7% | $352K | 29.7% | $-10,203,000 | -860.3% |
| 2025 | $1.3M | -5.5% | $619K | 48.7% | $-7,446,000 | -585.8% |
| 2024 | $1.3M | +47.6% | $733K | 54.5% | $-9,798,000 | -728.5% |
| 2023 | $911K | +129.5% | $-158,000 | -17.3% | $-11,571,000 | -1270.1% |
| 2022 | $397K | -55.8% | $194K | 48.9% | $-15,428,000 | -3886.1% |
| 2021 | $898K | -77.9% | $-349,000 | -38.9% | $-8,724,000 | -971.5% |
| 2020 | $4.1M | -20.4% | $115K | 2.8% | $-6,864,000 | -168.6% |
| 2019 | $5.1M | +133.3% | $132K | 2.6% | $-4,643,000 | -90.8% |
| 2018 | $2.2M | +277.9% | $82K | 3.7% | $-1,789,000 | -81.6% |
| 2017 | $580K | -90.9% | $218K | 37.6% | $-2,054,000 | -353.9% |
| 2016 | $6.4M | -17.1% | $843K | 13.2% | $-2,906,000 | -45.6% |
| 2015 | $7.7M | +237.9% | $580K | 7.5% | $-4,342,000 | -56.5% |
| 2014 | $2.3M | -71.7% | $382K | 16.8% | $-2,528,000 | -111.2% |
| 2013 | $8.0M | +91.2% | $1.5M | 19.1% | $-2,484,000 | -30.9% |
| 2012 | $4.2M | +3.1% | $-618,000 | -14.7% | $-7,512,000 | -178.9% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IGC — Frequently Asked Questions
Quick answers to the most common questions about buying IGC stock.
Is IGC's revenue growth accelerating or slowing?
IGC revenue growth is slowing. TTM revenue is $1M, up -3.9% year-over-year — below the 5-year CAGR of +5.7%. The deceleration suggests maturing end-markets or increased competition.
What is IGC's revenue history from 2006 to 2026?
IGC Pharma, Inc. (IGC) revenue history spans 2006 to 2026. TTM revenue as of 2026 is $1M, growing at -3.9% YoY. The 5-year CAGR is +5.7%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is IGC's long-term revenue growth rate (CAGR)?
IGC Pharma, Inc.'s 5-year revenue CAGR of +5.7% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -3.9% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for IGC.
Why does IGC's quarterly revenue fluctuate?
IGC quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. IGC Pharma, Inc.'s revenue data from 2006 to 2026 shows full historical quarterly detail on this page.
How is IGC's revenue distributed by segment?
IGC reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does IGC's revenue compare to industry peers?
IGC Pharma, Inc. (IGC) with TTM revenue of $1M and -3.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.